CN103826622B - 用于预防或治疗情感障碍的n-取代的苯丙酰胺或苯丙烯酰胺 - Google Patents
用于预防或治疗情感障碍的n-取代的苯丙酰胺或苯丙烯酰胺 Download PDFInfo
- Publication number
- CN103826622B CN103826622B CN201280045760.3A CN201280045760A CN103826622B CN 103826622 B CN103826622 B CN 103826622B CN 201280045760 A CN201280045760 A CN 201280045760A CN 103826622 B CN103826622 B CN 103826622B
- Authority
- CN
- China
- Prior art keywords
- compounds
- compound
- pharmaceutical composition
- treatment
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- DRAXYNLANLVNEN-UHFFFAOYSA-N CC(C)COC(C)COCC(Cc(cc1)ccc1O)NC(CCc1ccccc1)=O Chemical compound CC(C)COC(C)COCC(Cc(cc1)ccc1O)NC(CCc1ccccc1)=O DRAXYNLANLVNEN-UHFFFAOYSA-N 0.000 description 1
- YPRPFXQDLGOAKC-UHFFFAOYSA-N CC(COC(C)(c1ccccc1)c1ccccc1)O Chemical compound CC(COC(C)(c1ccccc1)c1ccccc1)O YPRPFXQDLGOAKC-UHFFFAOYSA-N 0.000 description 1
- BKNGPTVKNQLFIG-UHFFFAOYSA-N CC(COCC(Cc(cc1)ccc1O)NC(CCC1=CC=CCC1C)=O)O Chemical compound CC(COCC(Cc(cc1)ccc1O)NC(CCC1=CC=CCC1C)=O)O BKNGPTVKNQLFIG-UHFFFAOYSA-N 0.000 description 1
- 0 CCC(NC(Cc1ccccc1)COC(C)(C)CC(C)O**)=O Chemical compound CCC(NC(Cc1ccccc1)COC(C)(C)CC(C)O**)=O 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Cc1ccccc1 Chemical compound Cc1ccccc1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- DBLDQZASZZMNSL-UHFFFAOYSA-N NC(Cc(cc1)ccc1O)CO Chemical compound NC(Cc(cc1)ccc1O)CO DBLDQZASZZMNSL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/22—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1116335.9A GB201116335D0 (en) | 2011-09-21 | 2011-09-21 | A method of treating or preventing affective disorders |
| GB1116335.9 | 2011-09-21 | ||
| PCT/IB2012/054700 WO2013042005A1 (en) | 2011-09-21 | 2012-09-10 | N- substituted benzenepropanamide and benzenepropenamide for use in the prevention or the treatment of affective disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103826622A CN103826622A (zh) | 2014-05-28 |
| CN103826622B true CN103826622B (zh) | 2016-06-08 |
Family
ID=44937647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280045760.3A Expired - Fee Related CN103826622B (zh) | 2011-09-21 | 2012-09-10 | 用于预防或治疗情感障碍的n-取代的苯丙酰胺或苯丙烯酰胺 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9133103B2 (enExample) |
| EP (1) | EP2758046B1 (enExample) |
| JP (1) | JP6067022B2 (enExample) |
| CN (1) | CN103826622B (enExample) |
| AU (1) | AU2012311183B2 (enExample) |
| CA (1) | CA2849055C (enExample) |
| DK (1) | DK2758046T3 (enExample) |
| ES (1) | ES2559294T3 (enExample) |
| GB (1) | GB201116335D0 (enExample) |
| IL (1) | IL231609A (enExample) |
| WO (1) | WO2013042005A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015173813A1 (en) * | 2014-05-14 | 2015-11-19 | Novaremed Ltd. | Pharmaceutical composition comprising stereoisomers of n-(1-(4-hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide for the prevention and treatment of type ii diabetes |
| CN107011313B (zh) | 2016-01-27 | 2021-11-30 | 天士力医药集团股份有限公司 | 取代桂皮酰胺衍生物在制备抗焦虑药物中的应用 |
| EP3939578A1 (en) * | 2020-07-13 | 2022-01-19 | Novaremed Ltd. | Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005110987A1 (en) * | 2004-05-12 | 2005-11-24 | Pfizer Products Inc. | Piperidine derivatives as nk1 and nk3 antagonists |
| CN101180267A (zh) * | 2005-03-25 | 2008-05-14 | 制药有限责任公司 | 胺和氨基酸的苯基-n-酰基衍生物、其制备过程、其药物组合物和用途 |
| WO2009109850A2 (en) * | 2008-03-06 | 2009-09-11 | Novaremed Ltd. | A method of treating or preventing pain |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4667870B2 (ja) * | 2002-10-03 | 2011-04-13 | ノヴァレメッド リミテッド | 自己免疫疾患、免疫−アレルギー疾患及び臓器又は組織移植拒絶反応の治療において使用する新規な化合物 |
| JP4939396B2 (ja) * | 2004-03-26 | 2012-05-23 | ノヴァレメッド リミテッド | Ａｉｄｓ及び他のウイルス性疾患及びｈｉｖ関連感染症の改善又はその治療用化合物及びそのような化合物を含む組成物、そのような疾患及び感染症の治療方法及びそのような化合物及び組成物の製造方法 |
| CN102821761B (zh) | 2009-09-09 | 2015-06-10 | 诺瓦麦有限公司 | 用于治疗疼痛和炎症的n-取代的苯丙酰胺或苯丙烯酰胺 |
-
2011
- 2011-09-21 GB GBGB1116335.9A patent/GB201116335D0/en not_active Ceased
-
2012
- 2012-09-10 JP JP2014531340A patent/JP6067022B2/ja not_active Expired - Fee Related
- 2012-09-10 US US14/346,419 patent/US9133103B2/en not_active Expired - Fee Related
- 2012-09-10 CA CA2849055A patent/CA2849055C/en not_active Expired - Fee Related
- 2012-09-10 EP EP12780536.4A patent/EP2758046B1/en not_active Not-in-force
- 2012-09-10 CN CN201280045760.3A patent/CN103826622B/zh not_active Expired - Fee Related
- 2012-09-10 AU AU2012311183A patent/AU2012311183B2/en not_active Ceased
- 2012-09-10 WO PCT/IB2012/054700 patent/WO2013042005A1/en not_active Ceased
- 2012-09-10 DK DK12780536.4T patent/DK2758046T3/da active
- 2012-09-10 ES ES12780536.4T patent/ES2559294T3/es active Active
-
2014
- 2014-03-19 IL IL231609A patent/IL231609A/en active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005110987A1 (en) * | 2004-05-12 | 2005-11-24 | Pfizer Products Inc. | Piperidine derivatives as nk1 and nk3 antagonists |
| CN101180267A (zh) * | 2005-03-25 | 2008-05-14 | 制药有限责任公司 | 胺和氨基酸的苯基-n-酰基衍生物、其制备过程、其药物组合物和用途 |
| WO2009109850A2 (en) * | 2008-03-06 | 2009-09-11 | Novaremed Ltd. | A method of treating or preventing pain |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2849055C (en) | 2019-11-26 |
| AU2012311183B2 (en) | 2016-09-22 |
| IL231609A0 (en) | 2014-05-28 |
| HK1200353A1 (zh) | 2015-08-07 |
| JP2014530200A (ja) | 2014-11-17 |
| ES2559294T3 (es) | 2016-02-11 |
| CA2849055A1 (en) | 2013-03-28 |
| DK2758046T3 (da) | 2016-02-01 |
| IL231609A (en) | 2016-11-30 |
| US20140275273A1 (en) | 2014-09-18 |
| US9133103B2 (en) | 2015-09-15 |
| WO2013042005A1 (en) | 2013-03-28 |
| EP2758046A1 (en) | 2014-07-30 |
| EP2758046B1 (en) | 2015-10-21 |
| JP6067022B2 (ja) | 2017-01-25 |
| GB201116335D0 (en) | 2011-11-02 |
| CN103826622A (zh) | 2014-05-28 |
| AU2012311183A1 (en) | 2014-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5420534B2 (ja) | モノアミン再取り込み阻害薬としてのフェニル置換シクロアルキルアミン | |
| JP5901528B2 (ja) | 線維筋痛症候群の治療方法 | |
| KR20110025734A (ko) | 중추신경계 질환 및 질병 치료에 유효한 신규 화합물 | |
| JP6078059B2 (ja) | 置換シンナムアミド誘導体、その製造方法及び使用 | |
| CN110831584B (zh) | 具有新颖的组合物、组合的靶向药物拯救及其方法 | |
| JP2002508302A (ja) | 鎮痛薬として有用なα−アミノアミド誘導体 | |
| US20160317479A1 (en) | Method of treating or preventing pain | |
| CN103826622B (zh) | 用于预防或治疗情感障碍的n-取代的苯丙酰胺或苯丙烯酰胺 | |
| JP6016179B2 (ja) | 疼痛の治療又は予防用医薬組成物 | |
| EA019935B1 (ru) | Способы лечения алкогольной абстиненции | |
| PT2506842E (pt) | Formulações, sais e polimorfos de transnorsertralina e suas utilizações | |
| PT95735B (pt) | Processo para a preparacao de morfolinois e de composicoes farmaceuticas que os contem | |
| HK1200353B (en) | N-substituted benzenepropanamide and benzenepropenamide for use in the prevention or the treatment of affective disorders | |
| JP2008532992A (ja) | ベンゾキサゾシンおよびそれらの治療的使用 | |
| JP2020526592A (ja) | シクロベンザプリン類似体及びアミトリプチレン類似体 | |
| JP2019509321A (ja) | 疼痛を処置するための組み合わせ | |
| HK1179523B (en) | N-substituted benzenepropanamide or benzenepropenamide for use in the treatment of pain and inflammation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160608 Termination date: 20210910 |